Citius Oncology provides LYMPHIR launch update; commercialization planned for H1 2025

CITIUS ONCOLOGY, INC.

LYMPHIR (immunotherapy for CTCL) approved Aug 2024; launch targeted for first half of 2025.
First-year launch supply produced under commercial supply agreements with CMOs.
J-code application submitted under HCPCS; NCCN guidelines inclusion secured.
Patient assistance program and specialized field sales team under development.
Exploring international licensing partnerships and expanded indications for LYMPHIR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.